CanWell presented the preclinical research results of CAN1012, a small molecule TLR7 agonist in the form of an oral presentation at the 9th Immuno-oncology 360° (IO360°) conference.
The IO360° conference is a globally renowned annual conference for cancer immunotherapy, providing a collaboration opportunity for pharmaceutical/biotech companies, academia, and investors. The conference offers the platform where the latest progresses of cancer immunotherapy are shared and exchanged.